AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q1 2019 Earnings Presentation

30 slides from AMAG Pharmaceuticals's earnings presentation, May 7, 2019

  1. Slide 1: AMAG Pharmaceuticals First Quarter 2019 Financial Results

    AMAG Pharmaceuticals First Quarter 2019 Financial Results May 7, 2019 © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, AMAG

  3. Slide 3: Agenda

    Agenda 1 Q1-2019 Highlights and Recent Developments 2 Update on Commercial Products 3 Update on Development Pipeline Assets 4 Q1-2019 Financial Overview 5 Closing Remarks / Q&A © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 3

  4. Slide 4: Q1-2019 Highlights and Recent Developments

    Q1-2019 Highlights and Recent Developments • Promoted Tony Casciano to Chief Commercial Officer – Led the successful launches of the Makena subcutaneous (SC) auto-injector and the Feraheme broad label • Feraheme – Achieved 59% growth in Feraheme quarterly net sales year-over-year • Makena – SC auto-

  5. Slide 5: AMAG: Leveraging Two Strong Commercial Platforms

    AMAG: Leveraging Two Strong Commercial Platforms Hematology and Women’s/Maternal Health Future ciraparantag AMAG-423 Commercial Hematology Women’s Health Maternal Health 48 sales representatives => Heme clinics & hospitals 124 sales representatives => OB/GYNS Strong Commercial Platform © 2019 AMAG P

  6. Slide 6: Feraheme, Intrarosa, Makena, Vyleesi, Ciraparantag

    Feraheme® Intrarosa® Makena® VyleesiTM Ciraparantag 6

  7. Slide 7: Feraheme Continues to Grow with Expanded Label

    Feraheme Continues to Grow with Expanded Label Record First Quarter 2019 Revenue Feraheme Growth ($M) • Strong execution with expanded IDA label $40.0 – Performance-based contracting drove volume, with stable price 59% • Q1-2019 average market share was 16.1%, compared 1 $25.1 with 11.2% in Q1-2018

  8. Slide 8: Feraheme, Intrarosa, Makena, Vyleesi, Ciraparantag

    Feraheme® Intrarosa® Makena® VyleesiTM Ciraparantag 8

  9. Slide 9: Intrarosa Revenue and Market Share Trending Upward

    Intrarosa Revenue and Market Share Trending Upward Quarterly Revenue Intrarosa Overall Market Share1 Q1-2019 $8.0 ($M) • Rx market volume impacted by $7.0 deductible resets with start of new year $5.9 4.4% $6.0 TRx NRx 4.2% • Modified patient copay savings $5.0 program $4.4 4.0% $4.0 3.8% • Combinat

  10. Slide 10: Feraheme, Intrarosa, Makena, Vyleesi, Ciraparantag

    Feraheme® Intrarosa® Makena® VyleesiTM Ciraparantag 10

  11. Slide 11: Makena Revenue Q1-2019

    Makena Revenue Q1-2019 Strong SC auto-Injector volume growth overshadowed by gross-to-net charges Q1-2019 $46.9 • Makena SC auto-injector $45.8 ($3.5) ($5.0) – Recorded revenue of $37.8M $42.8 ($6.0) • Makena IM $35.1 $31.3 – Recorded $3.0M of profit share through AGx sales (limited supply) • Makena

  12. Slide 12: Continued Strong Physician Support of the SC Auto-injector

    Continued Strong Physician Support of the SC Auto-injector All FDA-approved hydroxyprogesterone caproate (HPC) TRxs1 Q4-2018 Q1-2019 SC Auto-injector Q1-2019 vs. Q4-2018 1% • Grew market share by 7 percentage points 9% 11% • Achieved 40% volume growth over Q4-2018 22% • Continued favorable payer and

  13. Slide 13: PROLONG Study – WSJ Article

    PROLONG Study – WSJ Article “Medical Groups Say It’s Too Early To Make A Call” March 18, 2019 “The American College of • PROLONG did not confirm the original efficacy results of the Obstetricians and Gynecologists, the Meis trial, but did confirm favorable safety profile Society for Maternal-Fetal M

  14. Slide 14: Feraheme, Intrarosa, Makena, Vyleesi, Ciraparantag

    TM Feraheme® Intrarosa® Makena® VyleesiTM Ciraparantag 14

  15. Slide 15: AMAG Data Presentations at ACOG Annual Meeting

    AMAG Data Presentations at ACOG Annual Meeting May 3-6  Nashville, TN Vyleesi (bremelanotide)1 Feraheme (ferumoxytol) Research Podium Session Research Poster Session “Bremelanotide for HSDD: Contraceptive Subgroups “Sustained Improvements in Anemia and Fatigue of AUB Efficacy Analysis” after a Sing

  16. Slide 16: Unbranded Disease State Awareness Campaigns Launched

    Unbranded Disease State Awareness Campaigns Launched Bremelanotide PDUFA date: June 23, 2019 Healthcare Provider (HCP) Direct-to-Consumer (DTC) Disease State Awareness Disease State Awareness Campaign Launch, March 2019 Campaign Launch, April 2019 — — • It’s Not About Sex campaign unblush campaign l

  17. Slide 17: Feraheme, Intrarosa, Makena, Vyleesi, Ciraparantag

    Feraheme® Intrarosa® Makena® VyleesiTM Ciraparantag 17

  18. Slide 18: Ciraparantag Clinical Development Program Progressing

    Ciraparantag Clinical Development Program Progressing Planning for End of Phase 2 meeting with FDA 2H-2019 prior to initiating Phase 3b/4 clinical trial • Whole blood clotting time (WBCT) is currently a manual Automated coagulometer measures WBCT in ~2 minutes measure of the time it takes for blood

  19. Slide 19: Financial Overview

    Financial Overview 19

  20. Slide 20: First Quarter Financial Results

    First Quarter Financial Results $M Q1-2019 Q1-20181 Makena $31.3 $90.0 Feraheme/MuGard 40.1 25.2 Intrarosa 4.4 2.2 • Operating expense summary Total revenues $75.8 $117.4 – Increases driven by: . Acquired IPR&D of ~$75M related to acquisition of Cost of product sales 18.5 63.9 Perosphere . Research

  21. Slide 21: Strong Balance Sheet

    Strong Balance Sheet ($M) 3/31/19 12/31/18 Cash, cash equivalents and investments $267 $394 Short-term debt: Convertible senior notes (2.5%) due Feb. 2019 $0 $21 Long-term debt: Convertible senior notes (3.25%) due 2022 $320 $320 FINANCIAL OVERVIEW © 2019 AMAG Pharmaceuticals, Inc. All rights reserv

  22. Slide 22: Reaffirming 2019 Financial Guidance

    Reaffirming 2019 Financial Guidance Key inputs and drivers of financial guidance • Revenues driven by – Continued growth of Feraheme, Makena SC auto-injector and Intrarosa ($M) 2019 Financial Guidance1 – Resolution of Makena IM supply issue – ~$20M in expected ciraparantag development milestone Tota

  23. Slide 23: AMAG's Growing Innovative Pipeline

    AMAG's Growing Innovative Pipeline Progress on 2019 goals Approved/ Phase 1 Phase 2 Phase 3 Regulatory Review Marketed Anticoagulant reversal agent Ciraparantag (potential for orphan drug designation) Treatment of iron deficiency anemia H E M A T O L O G Y AMAG-423 Treatment of severe preeclampsia D

  24. Slide 24: Significant Shareholder Value at AMAG

    Significant Shareholder Value at AMAG Historical Value Drivers Fund Future Value Drivers ciraparantag AMAG-423 Fundingfunding HISTORICAL Value of AMAG FUTURE Value of AMAG © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 24

  25. Slide 25: AMAG Analyst Day – May 22, 2019

    AMAG Analyst Day – May 22, 2019 FEATURED EXTERNAL SPEAKERS: AMAG-423 (in development for the treatment of severe preeclampsia) • John Barton, MD, OB/GYN, MFM specialist at Baptist Health, Lexington, KY • Baha Sibai, MD, Professor, Department of OB/GYN and Reproductive Sciences, UT Physicians Materna

  26. Slide 26: First Quarter 2019 Financial Results Q&A

    AMAG Pharmaceuticals First Quarter 2019 Financial Results Q&A © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 26

  27. Slide 27: Appendix

    Appendix 27

  28. Slide 28: Reconciliation of GAAP to Non-GAAP Financial Results

    Reconciliation of GAAP to Non-GAAP Financial Results $M Q1-2019 Q1-2018 Operating loss ($117.7) ($50.8) Depreciation and intangible asset amortization 4.4 53.2 Non-cash inventory step-up adjustments -- 2.2 Stock-based compensation 4.2 4.8 Acquisition-related costs 0.2 -- Adjustments to contingent co

  29. Slide 29: Reconciliation of GAAP to Non-GAAP 2019 Financial Guidance

    Reconciliation of GAAP to Non-GAAP 2019 Financial Guidance 2019 Financial Guidance ($M) Operating loss1 ($206) – ($176) Depreciation & intangible asset amortization 36 Stock-based compensation 22 Non-cash inventory step up and adjustments to contingent consideration 1 Acquired IPR&D 75 Restructuring

  30. Slide 30: AMAG Pharmaceuticals First Quarter 2019 Financial Results

    AMAG Pharmaceuticals First Quarter 2019 Financial Results May 7, 2019 © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 30

AMAG Pharmaceuticals — Q1 2019 Earnings Presentation on 6ix